COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02571062
Recruitment Status : Completed
First Posted : October 8, 2015
Last Update Posted : October 8, 2015
Information provided by (Responsible Party):
Drugs for Neglected Diseases

Brief Summary:

Phase 1 bioequivalence (BE) study. This study is for regulatory purpose to determine BE of the tablet formulation used in the clinical trials and the final marketed tablet formulation under fed condition.

The study will be an open-label, 2-treatment, 2-sequence, 4-period, single-dose, replicate crossover study under fed condition. The 4-period sequences for the replicate design will be TRTR and RTRT, where R designates the reference formulation and T the test formulation. Subject will be allocated randomly to one of the two sequences of treatments according to the randomization list.

Condition or disease Intervention/treatment Phase
Trypanosomiasis, African Drug: Fexinidazole Phase 1

Detailed Description:

Ideally, BE study should be conducted under fasting condition as this is considered to be the most sensitive condition to detect a potential difference between formulations. However as fexinidazole is recommended to be taken with food, as food increased the plasma concentration by 2.5 to 3 fold compared to plasma. BE will be conducted under fed condition, using field adapted meal. The wash-out period should be sufficient to ensure that drug concentrations are below the limit of quantification in all the subjects at the beginning of the next period, a 2 weeks wash-out period will be used. The intra-subject variability of fexinidazole was evaluated based on a previous 3-period cross-over study (1) and was estimated at 25%. As this value was quite high and close to 30%, a replicate design was chosen.

Primary objective:

To assess BE of the clinical trial 600 mg tablet formulation versus (vs.) the proposed market 600 mg tablet formulation of fexinidazole under fed condition after single oral administration of 1200 mg.

Secondary objectives:

To assess the pharmacokinetic profile of the two metabolites fexinidazole sulfoxide and fexinidazole sulfone under the fed condition. To assess the safety and tolerability in healthy volunteers under the same study conditions.

Meal: On each treatment period, fexinidazole will be given with concomitant meal which composition will be as close as possible to field condition

sample size: In order to have 24 evaluable subjects a total of 30 subjects will be recruited in the study.

Study Treatment: Single oral dose of 1200 mg / period :

  • Treatment R: Reference formulation, i.e. 2 × 600 mg clinical tablets
  • Treatment T: Test formulation, i.e. 2 × 600 mg proposed market tablets

Pharmacokinetic sampling: Pre-dose, and 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 120 and 168 h post-dose Total blood drawn: 390 mL ( Pharmacokinetic = 240 mL + safety = 150 mL)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Bioequivalence Study of the Reference Clinical Fexinidazole Tablet vs Proposed Market Formulation in Healthy Male Volunteers of African Sub-Saharan Origin:an Open-label,Randomized,Two-treatment,Single Dose,Replicate Design,Fed Condition
Study Start Date : March 2015
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Arm Intervention/treatment
Experimental: experimental formulation
crossover design
Drug: Fexinidazole
Experimental: final formulation
crossover design
Drug: Fexinidazole

Primary Outcome Measures :
  1. Pharmacokinetic parameters of fexinidazole following single dose [ Time Frame: Pharmacokinetic sampling: Pre-dose, and 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 120 and 168 h ]
    Area Under the Curve (AUC)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. All subjects to be of sub-Saharan African origins with both parents of sub- Saharan African origins too;
  2. Signed ICF;
  3. 18 to 45 years old
  4. Male subjects with a BMI calculated as weight (kg)/height (m)2 from 18 to 28 kg/m2 at screening
  5. Light smokers (less than 5 cigarettes per day, or equivalent e-cigarettes or nicotine patch) or subjects who are non-smokers. No smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening throughout the study;
  6. Normal arterial BP and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator. These will be measured after resting for 5 min;
  7. Normal ECG or, if abnormal, considered not clinically significant by the principal Investigator;
  8. Registered with the French Social Security in agreement with the French law on biomedical experimentation.

Exclusion Criteria:

  1. Who on direct questioning and physical examination have evidence of any clinically significant acute or chronic disease, including known or suspected HIV, HBV or HCV infection
  2. With any clinically significant abnormality following review of pre-study laboratory tests (ASAT, ALAT) must be within normal ranges), vital signs, full physical examination and ECG;
  3. Who are within the exclusion period defined in the National Register for Healthy Volunteers of the French Ministry of Health;
  4. Unwilling to give their informed consent;
  5. Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or anti-HIV 1/2 or anti- HCV antibodies;
  6. Who have a history of allergy, intolerance or photosensitivity to any drug;
  7. Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug;
  8. Who have a history of HAT;
  9. Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol);
  10. Who have a positive alcohol breath test
  11. Who drink more than 8 cups daily of beverage containing caffeine;
  12. Who have a positive laboratory test for urine drug screening (opiates, cocaine, amphetamine, cannabis, benzodiazepines);
  13. Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study;
  14. Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration;
  15. Who have already taken fexinidazole;
  16. Who have any clinical condition or prior therapy which, in the opinion of the Investigator, made the subject unsuitable for the study;
  17. Who participated to any clinical trial with an investigational drug in the past 3 months preceding the first study drug administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02571062

Layout table for location information
Rennes, France
Sponsors and Collaborators
Drugs for Neglected Diseases
Layout table for investigator information
Study Director: Antoine Tarral, MD Drugs for Neglected Diseases

Layout table for additonal information
Responsible Party: Drugs for Neglected Diseases Identifier: NCT02571062    
Other Study ID Numbers: DNDiHATFEX008
First Posted: October 8, 2015    Key Record Dates
Last Update Posted: October 8, 2015
Last Verified: June 2015
Keywords provided by Drugs for Neglected Diseases:
Additional relevant MeSH terms:
Layout table for MeSH terms
Trypanosomiasis, African
Euglenozoa Infections
Protozoan Infections
Parasitic Diseases